Stay updated with breaking news from Exact Sciences Stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
28.05.2024 - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. William Blair ...
Shares of Exact Sciences Corporation fell 4.4% In Tuesday’s post-market trading after the cancer screening and diagnostic tests provider reported lower-than-expected 4Q earnings. Meanwhile, exact Sciences (EXAS) posted a loss per share of $2.79 during the fourth quarter, which was higher than the $0.22 loss per share expected by analysts. Revenue increased about 58% year-on-year to $466.3 million topping analysts’ estimates of $446.22 million. During the quarter its screening revenue which includes revenue from Cologuard and Biomatrica products rose 9% to $249.7 million. Revenue ...